

CLAIMS

1. Use of an anti-TROP2 antibody-drug conjugate in the manufacture of a medicament for treating cancer, the antibody-drug conjugate comprising an anti-TROP2 antibody and an antitumor compound connected by a linker, wherein the linker and the antitumor compound are represented by the following formula:
-(Succinimid-3-yl-N)-$CH_2CH_2CH_2CH_2CH_2$-C(=O)-GGFG-NH-CH_2-O-CH_2-C(=O)-(NH-DX)
wherein -(Succinimid-3-yl-N)- has a structure represented by the following formula:



which is connected to the antibody at position 3 thereof and is connected to a methylene group in the linker structure containing this structure on the nitrogen atom at position 1, and (NH-DX) represents a group represented by the following formula:



wherein the nitrogen atom of the amino group at position 1 is the connecting position,
wherein the anti-TROP2 antibody comprises CDRH1 consisting of the amino acid sequence of SEQ ID NO: 23, CDRH2 consisting of the amino acid sequence of SEQ ID NO: 24 and CDRH3 consisting of the amino acid sequence of SEQ ID NO: 25 in its heavy chain variable region and CDRL1 consisting of the amino acid sequence of SEQ ID NO: 26, CDRL2 consisting of the amino acid sequence of SEQ ID NO: 27 and CDRL3 consisting of the amino acid sequence of SEQ ID NO: 28 in its light chain variable region,

wherein the antibody-drug conjugate is to be administered to a subject with cancer in a dose of 4 mg/kg or 6 mg/kg,

wherein the cancer is non-small cell lung cancer (NSCLC), breast cancer or urothelial cancer,

wherein the antibody-drug conjugate is to be administered once every 3 weeks or once every 4 weeks.

2. The use according to claim 1, wherein an average number of units of the antitumor compound conjugated per antibody is in a range of from 2 to 8 or 3 to 8.

3. The use according to claim 1 or 2, wherein an average number of units of the antitumor compound conjugated per antibody is 3.5 to 4.5.

4. The use according to any one of claims 1-3, wherein the antibody comprises a heavy chain variable region comprising amino acids 1-121 of SEQ ID NO: 45 and a light chain variable region comprising amino acids 1-109 of SEQ ID NO: 46.

5. The use according to any one of claims 1-4, wherein the antibody comprises a heavy chain comprising SEQ ID NO: 45 and a light chain comprising SEQ ID NO: 46.

6. The use according to any one of claims 1-5, wherein the anti-TROP2 antibody lacks a lysine residue at the carboxyl terminus of the heavy chain.

7. The use according to any one of claims 1-6, wherein the antibody-drug conjugate is to be administered by intravenous administration.

8. The use according to any one of claim 1-7, wherein the cancer is non-small cell lung cancer (NSCLC).

9. The use according to any one of claim 1-7, wherein the cancer is breast cancer.

10. The use according to any one of claim 1-7, wherein the cancer is urothelial cancer.

11. The use according to any one of claims 1-10, wherein the cancer is resistant or refractory.

12. The use according to claim 11, wherein the resistance or refractoriness is resistance or refractoriness acquired by the cancer due to treatment with an anticancer drug.

13. The use according to claim 12, wherein the anticancer drug is an EGFR-inhibitor, an ALK-inhibitor, a platinum-based chemotherapeutic, or a checkpoint inhibitor.

14. The use according to claim 12, wherein the anticancer drug is gefitinib, erlotinib, osimertinib, affatinib, alectinib, crizotinib, ceritinib, cisplatin, carboplatin, nivolumab, pembrolizumab, atezolizumab, avelumab, ipilimumab, durvalumab, tislelizumab, sintilimab, or cemiplimab.

15. The use according to any one of claims 1-14, wherein the cancer is a TROP2-expressing cancer.

16. The use according to claim 15, wherein the TROP2-expressing cancer is TROP2-overexpressing cancer.

17. The use according to any one of claims 1-16, wherein the cancer is an inoperable or recurrent cancer.

18. The use according to any one of claims 1-17, wherein the antibody-drug conjugate is to be administered in a pharmaceutical composition comprising at least one pharmaceutically acceptable formulation component.